


WHAT IS CLAIMED IS:

1. A compound of formula I:



I

5 or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

A is selected from  $-\text{COR}^5$ ,  $-\text{CO}_2\text{H}$ ,  $\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{R}^6$ ,  $-\text{CONHOH}$ ,  
 $-\text{CONHOR}^5$ ,  $-\text{CONHOR}^6$ ,  $-\text{N}(\text{OH})\text{COR}^5$ ,  $-\text{N}(\text{OH})\text{CHO}$ ,  $-\text{SH}$ ,  
 10  $-\text{CH}_2\text{SH}$ ,  $-\text{S}(\text{O})(=\text{NH})\text{R}^a$ ,  $-\text{SN}_2\text{H}_2\text{R}^a$ ,  $-\text{PO}(\text{OH})_2$ , and  
 $-\text{PO}(\text{OH})\text{NHR}^a$ ;

ring B is a 3-13 membered non-aromatic carbocyclic or  
 heterocyclic ring comprising: carbon atoms, 0-3  
 15 carbonyl groups, 0-4 double bonds, and from 0-2 ring  
 heteroatoms selected from O, N,  $\text{NR}^2$ , and  $\text{S}(\text{O})_p$ ,  
 provided that ring B contains other than a S-S, O-O,  
 or S-O bond;

20 Z is absent or selected from a  $\text{C}_{3-13}$  carbocycle  
 substituted with 0-5  $\text{R}^b$  and a 5-14 membered  
 heterocycle comprising: carbon atoms and 1-4  
 heteroatoms selected from the group consisting of N,  
 O, and  $\text{S}(\text{O})_p$  and substituted with 0-5  $\text{R}^b$ ;

25  $\text{U}^a$  is absent or is selected from: O,  $\text{NR}^{a1}$ ,  $\text{C}(\text{O})$ ,  $\text{C}(\text{O})\text{O}$ ,  
 $\text{OC}(\text{O})$ ,  $\text{C}(\text{O})\text{NR}^{a1}$ ,  $\text{NR}^{a1}\text{C}(\text{O})$ ,  $\text{OC}(\text{O})\text{O}$ ,  $\text{OC}(\text{O})\text{NR}^{a1}$ ,  
 $\text{NR}^{a1}\text{C}(\text{O})\text{O}$ ,  $\text{NR}^{a1}\text{C}(\text{O})\text{NR}^{a1}$ ,  $\text{S}(\text{O})_p$ ,  $\text{S}(\text{O})_p\text{NR}^{a1}$ ,  $\text{NR}^{a1}\text{S}(\text{O})_p$ ,  
 and  $\text{NR}^{a1}\text{SO}_2\text{NR}^{a1}$ ;

30

$X^a$  is absent or selected from  $C_{1-10}$  alkylene,  $C_{2-10}$  alkenylene, and  $C_{2-10}$  alkynylene;

$Y^a$  is absent or selected from O,  $NR^{a1}$ ,  $S(O)_p$ , and  $C(O)$ ;

5

$Z^a$  is selected from H, a  $C_{3-13}$  carbocycle substituted with 0-5  $R^c$  and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$  and substituted with 0-5  $R^c$ ;

10

provided that Z,  $U^a$ ,  $Y^a$ , and  $Z^a$  do not combine to form a N-N, N-O, O-N, O-O,  $S(O)_p$ -O, O- $S(O)_p$  or  $S(O)_p$ - $S(O)_p$  group;

15

$R^1$  is selected from H,  $C_{1-4}$  alkyl, phenyl, and benzyl;

$R^2$  is selected from Q, Cl, F,  $C_{1-10}$  alkylene-Q substituted with 0-3  $R^{b1}$ ,  $C_{2-10}$  alkenylene-Q substituted with 0-3  $R^{b1}$ ,  $C_{2-10}$  alkynylene-Q substituted with 0-3  $R^{b1}$ ,

20

$(CR^aRa^1)_rO(CR^aRa^1)_r-Q$ ,  $(CR^aRa^1)_rNR^a(CR^aRa^1)_r-Q$ ,  
 $(CR^aRa^1)_rC(O)(CR^aRa^1)_r-Q$ ,  $(CR^aRa^1)_rC(O)O(CR^aRa^1)_r-Q$ ,  
 $(CR^aRa^1)_rC(O)O-C_{2-5}$  alkenylene,  $(CR^aRa^1)_rC(O)O-C_{2-5}$  alkynylene,  
 $(CR^aRa^1)_rOC(O)(CR^aRa^1)_r-Q$ ,

25

$(CR^aRa^1)_rC(O)NR^aRa^1$ ,  $(CR^aRa^1)_rC(O)NR^a(CR^aRa^1)_r-Q$ ,  
 $(CR^aRa^1)_rNR^aC(O)(CR^aRa^1)_r-Q$ ,  
 $(CR^aRa^1)_rOC(O)O(CR^aRa^1)_r-Q$ ,  
 $(CR^aRa^1)_rOC(O)NR^a(CR^aRa^1)_r-Q$ ,  
 $(CR^aRa^1)_rNR^aC(O)O(CR^aRa^1)_r-Q$ ,

30

$(CR^aRa^1)_rNR^aC(O)NR^a(CR^aRa^1)_r-Q$ ,  
 $(CR^aRa^1)_rS(O)_p(CR^aRa^1)_r-Q$ ,  $(CR^aRa^1)_rSO_2NR^a(CR^aRa^1)_r-Q$ ,

$(\text{CR}^a\text{Ra}^1)_r\text{NR}^a\text{SO}_2(\text{CR}^a\text{Ra}^1)_r\text{-Q}$ , and  
 $(\text{CR}^a\text{Ra}^1)_r\text{NR}^a\text{SO}_2\text{NR}^a(\text{CR}^a\text{Ra}^1)_r\text{-Q}$ ;

$\text{R}^{2a}$  is selected from H,  $\text{C}_{1-6}$  alkyl,  $\text{OR}^a$ ,  $\text{NR}^a\text{Ra}^1$ , and  
 5  $\text{S(O)}_p\text{Ra}^1$ ;

$\text{R}^{2b}$  is H or  $\text{C}_{1-6}$  alkyl;

$\text{Q}$  is selected from H, a  $\text{C}_{3-13}$  carbocycle substituted with  
 10 0-5  $\text{R}^d$  and a 5-14 membered heterocycle comprising:  
 carbon atoms and 1-4 heteroatoms selected from the  
 group consisting of N, O, and  $\text{S(O)}_p$  and substituted  
 with 0-5  $\text{R}^d$ ;

15  $\text{R}^3$  is selected from  $\text{Q}^1$ , Cl, F,  $\text{C}_{1-6}$  alkylene- $\text{Q}^1$ ,  $\text{C}_{2-6}$   
 alkenylene- $\text{Q}^1$ ,  $\text{C}_{2-6}$  alkynylene- $\text{Q}^1$ ,  
 $(\text{CR}^a\text{Ra}^1)_r\text{O}(\text{CR}^a\text{Ra}^1)_r\text{-Q}^1$ ,  $(\text{CR}^a\text{Ra}^1)_r\text{NR}^a(\text{CR}^a\text{Ra}^1)_r\text{-Q}^1$ ,  
 $(\text{CR}^a\text{Ra}^1)_r\text{NR}^a\text{C(O)}(\text{CR}^a\text{Ra}^1)_r\text{-Q}^1$ ,  
 $(\text{CR}^a\text{Ra}^1)_r\text{C(O)}\text{NR}^a(\text{CR}^a\text{Ra}^1)_r\text{-Q}^1$ ,  $(\text{CR}^a\text{Ra}^1)_r\text{C(O)}(\text{CR}^a\text{Ra}^1)_r\text{-Q}^1$ ,  
 20  $(\text{CR}^a\text{Ra}^1)_r\text{C(O)}\text{O}(\text{CR}^a\text{Ra}^1)_r\text{-Q}^1$ ,  $(\text{CR}^a\text{Ra}^1)_2\text{rS(O)}_p(\text{CR}^a\text{Ra}^1)_r\text{-Q}^1$ ,  
 and  $(\text{CR}^a\text{Ra}^1)_r\text{SO}_2\text{NR}^a(\text{CR}^a\text{Ra}^1)_r\text{-Q}^1$ ;

$\text{Q}^1$  is selected from H, phenyl substituted with 0-3  $\text{R}^d$ ,  
 naphthyl substituted with 0-3  $\text{R}^d$  and a 5-10 membered  
 25 heteroaryl comprising: carbon atoms and 1-4  
 heteroatoms selected from the group consisting of N,  
 O, and  $\text{S(O)}_p$  and substituted with 0-3  $\text{R}^d$ ;

$\text{R}^a$ , at each occurrence, is independently selected from H,  
 30  $\text{C}_{1-4}$  alkyl, phenyl and benzyl;

$R^{a1}$ , at each occurrence, is independently selected from H and  $C_{1-4}$  alkyl;

alternatively,  $R^a$  and  $R^{a1}$  when attached to a nitrogen are  
 5 taken together with the nitrogen to which they are attached to form a 5 or 6 membered ring comprising carbon atoms and from 0-1 additional heteroatoms selected from the group consisting of N, O, and  $S(O)_p$ ;

10

$R^{a2}$ , at each occurrence, is independently selected from  $C_{1-4}$  alkyl, phenyl and benzyl;

$R^b$ , at each occurrence, is independently selected from  
 15  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, I, =O, -CN,  $NO_2$ ,  $NR^aR^{a1}$ ,  $C(O)R^a$ ,  $C(O)OR^a$ ,  $C(O)NR^aR^{a1}$ ,  $R^aNC(O)NR^aR^{a1}$ ,  $OC(O)NR^aR^{a1}$ ,  $R^aNC(O)O$ ,  $S(O)_2NR^aR^{a1}$ ,  $NR^aS(O)_2R^{a2}$ ,  $NR^aS(O)_2NR^aR^{a1}$ ,  $OS(O)_2NR^aR^{a1}$ ,  $NR^aS(O)_2R^{a2}$ ,  $S(O)_pR^{a2}$ ,  $CF_3$ , and  $CF_2CF_3$ ;

20

$R^{b1}$ , at each occurrence, is independently selected from  $OR^a$ , Cl, F, Br, I, =O, -CN,  $NO_2$ , and  $NR^aR^{a1}$ ;

$R^c$ , at each occurrence, is independently selected from  
 25  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, I, =O, -CN,  $NO_2$ ,  $NR^aR^{a1}$ ,  $C(O)R^a$ ,  $C(O)OR^a$ ,  $C(O)NR^aR^{a1}$ ,  $R^aNC(O)NR^aR^{a1}$ ,  $OC(O)NR^aR^{a1}$ ,  $R^aNC(O)O$ ,  $S(O)_2NR^aR^{a1}$ ,  $NR^aS(O)_2R^{a2}$ ,  $NR^aS(O)_2NR^aR^{a1}$ ,  $OS(O)_2NR^aR^{a1}$ ,  $NR^aS(O)_2R^{a2}$ ,  $S(O)_pR^{a2}$ ,  $CF_3$ ,  $CF_2CF_3$ ,  $C_{3-10}$  carbocycle substituted with 0-3  $R^{c1}$   
 30 and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$  and substituted with 0-3  $R^{c1}$ ;

$R^{c1}$ , at each occurrence, is independently selected from  
 $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, I,  $=O$ ,  $-CN$ ,  $NO_2$ ,  $NR^aR^{a1}$ ,  
 $C(O)R^a$ ,  $C(O)OR^a$ ,  $C(O)NR^aR^{a1}$ ,  $R^aNC(O)NR^aR^{a1}$ ,  
5  $OC(O)NR^aR^{a1}$ ,  $R^aNC(O)O$ ,  $S(O)_2NR^aR^{a1}$ ,  $NR^aS(O)_2R^{a2}$ ,  
 $NR^aS(O)_2NR^aR^{a1}$ ,  $OS(O)_2NR^aR^{a1}$ ,  $NR^aS(O)_2R^{a2}$ ,  $S(O)_pR^{a2}$ ,  
 $CF_3$ , and  $CF_2CF_3$ ;

$R^d$ , at each occurrence, is independently selected from  
10  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, I,  $=O$ ,  $-CN$ ,  $NO_2$ ,  $NR^aR^{a1}$ ,  
 $C(O)R^a$ ,  $C(O)OR^a$ ,  $C(O)NR^aR^{a1}$ ,  $R^aNC(O)NR^aR^{a1}$ ,  
 $OC(O)NR^aR^{a1}$ ,  $R^aNC(O)O$ ,  $S(O)_2NR^aR^{a1}$ ,  $NR^aS(O)_2R^{a2}$ ,  
 $NR^aS(O)_2NR^aR^{a1}$ ,  $OS(O)_2NR^aR^{a1}$ ,  $NR^aS(O)_2R^{a2}$ ,  $S(O)_pR^{a2}$ ,  
 $CF_3$ ,  $CF_2CF_3$ ,  $C_{3-10}$  carbocycle and a 5-14 membered  
15 heterocycle comprising: carbon atoms and 1-4  
heteroatoms selected from the group consisting of N,  
O, and  $S(O)_p$ ;

$R^5$ , at each occurrence, is selected from  $C_{1-10}$  alkyl  
20 substituted with 0-2  $R^b$ , and  $C_{1-8}$  alkyl substituted  
with 0-2  $R^e$ ;

$R^e$ , at each occurrence, is selected from phenyl  
substituted with 0-2  $R^b$  and biphenyl substituted  
25 with 0-2  $R^b$ ;

$R^6$ , at each occurrence, is selected from phenyl,  
naphthyl,  $C_{1-10}$  alkyl-phenyl- $C_{1-6}$  alkyl-,  $C_{3-11}$   
cycloalkyl,  $C_{1-6}$  alkylcarbonyloxy- $C_{1-3}$  alkyl-,  $C_{1-6}$   
30 alkoxycarbonyloxy- $C_{1-3}$  alkyl-,  $C_{2-10}$  alkoxycarbonyl,  
 $C_{3-6}$  cycloalkylcarbonyloxy- $C_{1-3}$  alkyl-,  $C_{3-6}$   
cycloalkoxycarbonyloxy- $C_{1-3}$  alkyl-,  $C_{3-6}$

cycloalkoxycarbonyl, phenoxycarbonyl,  
 phenyloxycarbonyloxy-C<sub>1-3</sub> alkyl-,  
 phenylcarbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>1-6</sub> alkoxy-C<sub>1-6</sub>  
 alkylcarbonyloxy-C<sub>1-3</sub> alkyl-, [5-(C<sub>1</sub>-C<sub>5</sub>  
 5 alkyl)-1,3-dioxo-cyclopenten-2-one-yl]methyl,  
 [5-(R<sup>a</sup>)-1,3-dioxo-cyclopenten-2-one-yl]methyl,  
 (5-aryl-1,3-dioxo-cyclopenten-2-one-yl)methyl,  
 -C<sub>1-10</sub> alkyl-NR<sup>7</sup>R<sup>7a</sup>, -CH(R<sup>8</sup>)OC(=O)R<sup>9</sup>, and  
 -CH(R<sup>8</sup>)OC(=O)OR<sup>9</sup>;  
 10

R<sup>7</sup> is selected from H and C<sub>1-10</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>3-6</sub>  
 cycloalkyl-C<sub>1-3</sub> alkyl-, and phenyl-C<sub>1-6</sub> alkyl-;

R<sup>7a</sup> is selected from H and C<sub>1-10</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>3-6</sub>  
 15 cycloalkyl-C<sub>1-3</sub> alkyl-, and phenyl-C<sub>1-6</sub> alkyl-;

R<sup>8</sup> is selected from H and C<sub>1-4</sub> linear alkyl;

R<sup>9</sup> is selected from H, C<sub>1-8</sub> alkyl substituted with 1-2 R<sup>f</sup>,  
 20 C<sub>3-8</sub> cycloalkyl substituted with 1-2 R<sup>f</sup>, and phenyl  
 substituted with 0-2 R<sup>b</sup>;


R<sup>f</sup>, at each occurrence, is selected from C<sub>1-4</sub> alkyl, C<sub>3-8</sub>  
 cycloalkyl, C<sub>1-5</sub> alkoxy, and phenyl substituted with  
 25 0-2 R<sup>b</sup>;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and  
 30 4; and,

r<sup>1</sup>, at each occurrence, is selected from 0, 1, 2, 3, and  
 4.

2. A compound according to Claim 1, wherein the compound is of formula II:



II

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

- 10 A is selected from  $-\text{CO}_2\text{H}$ ,  $\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CONHOH}$ ,  $-\text{CONHOR}^5$ ,  $-\text{CONHOR}^6$ ,  $-\text{N}(\text{OH})\text{COR}^5$ ,  $-\text{N}(\text{OH})\text{CHO}$ ,  $-\text{SH}$ , and  $-\text{CH}_2\text{SH}$ ;

- 15 ring B is a 4-7 membered non-aromatic carbocyclic or heterocyclic ring comprising: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, and  $\text{NR}^2$ , provided that ring B contains other than a O-O bond;

- 20 Z is absent or selected from a  $\text{C}_{3-11}$  carbocycle substituted with 0-4  $\text{R}^b$  and a 5-11 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $\text{S}(\text{O})_p$  and substituted with 0-3  $\text{R}^b$ ;

- 25  $\text{U}^a$  is absent or is selected from: O,  $\text{NR}^{a1}$ ,  $\text{C}(\text{O})$ ,  $\text{C}(\text{O})\text{O}$ ,  $\text{C}(\text{O})\text{NR}^{a1}$ ,  $\text{NR}^{a1}\text{C}(\text{O})$ ,  $\text{S}(\text{O})_p$ , and  $\text{S}(\text{O})_p\text{NR}^{a1}$ ;

$\text{X}^a$  is absent or selected from  $\text{C}_{1-4}$  alkylene,  $\text{C}_{2-4}$  alkenylene, and  $\text{C}_{2-4}$  alkynylene;

30

$Y^a$  is absent or selected from O and  $NR^{a^1}$ ;

$Z^a$  is selected from H, a  $C_{3-10}$  carbocycle substituted with  
 0-5  $R^c$  and a 5-10 membered heterocycle comprising:  
 5 carbon atoms and 1-4 heteroatoms selected from the  
 group consisting of N, O, and  $S(O)_p$  and substituted  
 with 0-5  $R^c$ ;

provided that Z,  $U^a$ ,  $Y^a$ , and  $Z^a$  do not combine to form a  
 10 N-N, N-O, O-N, O-O,  $S(O)_p$ -O, O- $S(O)_p$  or  $S(O)_p$ - $S(O)_p$   
 group;

$R^1$  is selected from H,  $C_{1-4}$  alkyl, phenyl, and benzyl;

15  $R^2$  is selected from Q,  $C_{1-6}$  alkylene-Q,  $C_{2-6}$  alkenylene-Q,  
 $C_{2-6}$  alkynylene-Q,  $(CR^aRa^1)_rO(CR^aRa^1)_r-Q$ ,  
 $(CR^aRa^1)_rNR^a(CR^aRa^1)_r-Q$ ,  $(CR^aRa^1)_rC(O)(CR^aRa^1)_r-Q$ ,  
 $(CR^aRa^1)_rC(O)O(CR^aRa^1)_r-Q$ ,  $(CR^aRa^1)_rC(O)NR^aRa^1$ ,  
 $(CR^aRa^1)_rC(O)NR^a(CR^aRa^1)_r-Q$ ,  $(CR^aRa^1)_rS(O)_p(CR^aRa^1)_r-Q$ ,  
 20 and  $(CR^aRa^1)_rSO_2NR^a(CR^aRa^1)_r-Q$ ;

Q is selected from H, a  $C_{3-6}$  carbocycle substituted with  
 0-5  $R^d$ , and a 5-10 membered heterocycle comprising:  
 carbon atoms and 1-4 heteroatoms selected from the  
 25 group consisting of N, O, and  $S(O)_p$  and substituted  
 with 0-5  $R^d$ ;

$R^a$ , at each occurrence, is independently selected from H,  
 $C_{1-4}$  alkyl, phenyl and benzyl;

30  $R^{a^1}$ , at each occurrence, is independently selected from H  
 and  $C_{1-4}$  alkyl;



alternatively,  $R^a$  and  $R^{a^1}$  when attached to a nitrogen are taken together with the nitrogen to which they are attached to form a 5 or 6 membered ring comprising carbon atoms and from 0-1 additional heteroatoms  
 5 selected from the group consisting of N, O, and S(O)<sub>p</sub>;

$R^{a^2}$ , at each occurrence, is independently selected from C<sub>1-4</sub> alkyl, phenyl and benzyl;

10

$R^b$ , at each occurrence, is independently selected from C<sub>1-6</sub> alkyl, OR<sup>a</sup>, Cl, F, Br, =O, -CN, NR<sup>a</sup>R<sup>a<sup>1</sup></sup>, C(O)R<sup>a</sup>, C(O)OR<sup>a</sup>, C(O)NR<sup>a</sup>R<sup>a<sup>1</sup></sup>, S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a<sup>1</sup></sup>, S(O)<sub>p</sub>R<sup>a<sup>2</sup></sup>, and CF<sub>3</sub>;

15  $R^c$ , at each occurrence, is independently selected from C<sub>1-6</sub> alkyl, OR<sup>a</sup>, Cl, F, Br, =O, -CN, NR<sup>a</sup>R<sup>a<sup>1</sup></sup>, C(O)R<sup>a</sup>, C(O)OR<sup>a</sup>, C(O)NR<sup>a</sup>R<sup>a<sup>1</sup></sup>, S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a<sup>1</sup></sup>, S(O)<sub>p</sub>R<sup>a<sup>2</sup></sup>, CF<sub>3</sub>, C<sub>3-6</sub> carbocycle and a 5-6 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms  
 20 selected from the group consisting of N, O, and S(O)<sub>p</sub>;

$R^d$ , at each occurrence, is independently selected from C<sub>1-6</sub> alkyl, OR<sup>a</sup>, Cl, F, Br, =O, -CN, NR<sup>a</sup>R<sup>a<sup>1</sup></sup>, C(O)R<sup>a</sup>,  
 25 C(O)OR<sup>a</sup>, C(O)NR<sup>a</sup>R<sup>a<sup>1</sup></sup>, S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a<sup>1</sup></sup>, S(O)<sub>p</sub>R<sup>a<sup>2</sup></sup>, CF<sub>3</sub>, C<sub>3-6</sub> carbocycle and a 5-6 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub>;

30

$R^5$ , at each occurrence, is selected from C<sub>1-6</sub> alkyl substituted with 0-2  $R^b$ , and C<sub>1-4</sub> alkyl substituted with 0-2  $R^e$ ;

R<sup>e</sup>, at each occurrence, is selected from phenyl substituted with 0-2 R<sup>b</sup> and biphenyl substituted with 0-2 R<sup>b</sup>;

5

R<sup>6</sup>, at each occurrence, is selected from phenyl, naphthyl, C<sub>1-10</sub> alkyl-phenyl-C<sub>1-6</sub> alkyl-, C<sub>3-11</sub> cycloalkyl, C<sub>1-6</sub> alkylcarbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>1-6</sub> alkoxy carbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>2-10</sub> alkoxy carbonyl, C<sub>3-6</sub> cycloalkylcarbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>3-6</sub> cycloalkoxy carbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>3-6</sub> cycloalkoxy carbonyl, phenoxycarbonyl, phenyloxy carbonyloxy-C<sub>1-3</sub> alkyl-, phenylcarbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>1-6</sub> alkoxy-C<sub>1-6</sub> alkylcarbonyloxy-C<sub>1-3</sub> alkyl-, [5-(C<sub>1-5</sub> alkyl)-1,3-dioxo-cyclopenten-2-one-yl]methyl, [5-(R<sup>a</sup>)-1,3-dioxo-cyclopenten-2-one-yl]methyl, (5-aryl-1,3-dioxo-cyclopenten-2-one-yl)methyl, -C<sub>1-10</sub> alkyl-NR<sup>7</sup>R<sup>7a</sup>, -CH(R<sup>8</sup>)OC(=O)R<sup>9</sup>, and -CH(R<sup>8</sup>)OC(=O)OR<sup>9</sup>;

20

R<sup>7</sup> is selected from H and C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>3-6</sub> cycloalkyl-C<sub>1-3</sub> alkyl-, and phenyl-C<sub>1-6</sub> alkyl-;

25 R<sup>7a</sup> is selected from H and C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>3-6</sub> cycloalkyl-C<sub>1-3</sub> alkyl-, and phenyl-C<sub>1-6</sub> alkyl-;

R<sup>8</sup> is selected from H and C<sub>1-4</sub> linear alkyl;

30 R<sup>9</sup> is selected from H, C<sub>1-6</sub> alkyl substituted with 1-2 R<sup>f</sup>, C<sub>3-6</sub> cycloalkyl substituted with 1-2 R<sup>f</sup>, and phenyl substituted with 0-2 R<sup>b</sup>;


$R^f$ , at each occurrence, is selected from  $C_{1-4}$  alkyl,  $C_{3-6}$  cycloalkyl,  $C_{1-5}$  alkoxy, and phenyl substituted with 0-2  $R^b$ ;

5  $p$ , at each occurrence, is selected from 0, 1, and 2;


$r$ , at each occurrence, is selected from 0, 1, 2, 3, and 4; and,

10  $r^1$ , at each occurrence, is selected from 0, 1, 2, 3, and 4.

3. A compound according to Claim 2, wherein the  
15 compound is of formula IIIa or IIIb:



IIIa



IIIb

or a stereoisomer or pharmaceutically acceptable salt  
form thereof, wherein;

20

A is selected from  $-CO_2H$ ,  $CH_2CO_2H$ ,  $-CONHOH$ ,  $-CONHOR^5$ ,  
 $-N(OH)CHO$ , and  $-N(OH)COR^5$ ;

Z is absent or selected from a  $C_{5-6}$  carbocycle substituted  
25 with 0-3  $R^b$  and a 5-6 membered heteroaryl comprising  
carbon atoms and from 1-4 heteroatoms selected from  
the group consisting of N, O, and  $S(O)_p$  and  
substituted with 0-3  $R^b$ ;

30  $U^a$  is absent or is selected from: O,  $NR^{a1}$ ,  $C(O)$ ,  $C(O)NR^{a1}$ ,  
 $S(O)_p$ , and  $S(O)_pNR^{a1}$ ;

$X^a$  is absent or selected from  $C_{1-4}$  alkylene,  $C_{2-4}$  alkenylene, and  $C_{2-4}$  alkynylene

5  $Y^a$  is absent or selected from O and  $NR^{a^1}$ ;

$Z^a$  is selected from H, a  $C_{5-6}$  carbocycle substituted with 0-3  $R^c$  and a 5-10 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$  and substituted with 0-3  $R^c$ ;

10

provided that Z,  $U^a$ ,  $Y^a$ , and  $Z^a$  do not combine to form a N-N, N-O, O-N, O-O,  $S(O)_p$ -O, O- $S(O)_p$  or  $S(O)_p$ - $S(O)_p$  group;

15

$R^1$  is selected from H,  $C_{1-4}$  alkyl, phenyl, and benzyl;

$R^2$  is selected from Q,  $C_{1-6}$  alkylene-Q,  $C_{2-6}$  alkenylene-Q,  $C_{2-6}$  alkynylene-Q,  $(CR^aRa^1)_rC(O)(CR^aRa^1)_r-Q$ ,  $(CR^aRa^1)_rC(O)O(CR^aRa^1)_r-Q$ ,  $(CR^aRa^2)_rC(O)NR^aRa^1$ ,  $(CR^aRa^2)_rC(O)NR^a(CR^aRa^1)_r-Q$ , and  $(CR^aRa^1)_rS(O)_p(CR^aRa^1)_r-Q$ ;

20

25 Q is selected from H, a  $C_{3-6}$  carbocycle substituted with 0-3  $R^d$  and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$  and substituted with 0-3  $R^d$ ;

30

$R^a$ , at each occurrence, is independently selected from H,  $C_{1-4}$  alkyl, phenyl and benzyl;

R<sup>a1</sup>, at each occurrence, is independently selected from H  
and C<sub>1-4</sub> alkyl;

5 R<sup>a2</sup>, at each occurrence, is independently selected from  
C<sub>1-4</sub> alkyl, phenyl, and benzyl;

10 R<sup>b</sup>, at each occurrence, is independently selected from  
C<sub>1-4</sub> alkyl, OR<sup>a</sup>, Cl, F, =O, NR<sup>a</sup>R<sup>a1</sup>, C(O)R<sup>a</sup>, C(O)OR<sup>a</sup>,  
C(O)NR<sup>a</sup>R<sup>a1</sup>, S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, S(O)<sub>p</sub>R<sup>a2</sup>, and CF<sub>3</sub>;

R<sup>c</sup>, at each occurrence, is independently selected from  
C<sub>1-6</sub> alkyl, OR<sup>a</sup>, Cl, F, Br, =O, NR<sup>a</sup>R<sup>a1</sup>, C(O)R<sup>a</sup>,  
C(O)NR<sup>a</sup>R<sup>a1</sup>, S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, S(O)<sub>p</sub>R<sup>a2</sup>, and CF<sub>3</sub>;

15 R<sup>d</sup>, at each occurrence, is independently selected from  
C<sub>1-6</sub> alkyl, OR<sup>a</sup>, Cl, F, Br, =O, NR<sup>a</sup>R<sup>a1</sup>, C(O)R<sup>a</sup>,  
C(O)NR<sup>a</sup>R<sup>a1</sup>, S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, S(O)<sub>p</sub>R<sup>a2</sup>, CF<sub>3</sub>, and phenyl;

20 R<sup>5</sup>, at each occurrence, is selected from C<sub>1-4</sub> alkyl  
substituted with 0-2 R<sup>b</sup>, and C<sub>1-4</sub> alkyl substituted  
with 0-2 R<sup>e</sup>;

25 R<sup>e</sup>, at each occurrence, is selected from phenyl  
substituted with 0-2 R<sup>b</sup> and biphenyl substituted  
with 0-2 R<sup>b</sup>;



p, at each occurrence, is selected from 0, 1, and 2;

30 r, at each occurrence, is selected from 0, 1, 2, 3, and  
4;

r<sup>1</sup>, at each occurrence, is selected from 0, 1, 2, 3, and  
4; and,

s and  $s^1$  combine to total 2, 3, or 4.

5           4. A compound according to Claim 3, wherein the  
compound is of formula IVa or IVb:



or a stereoisomer or pharmaceutically acceptable salt  
10 form thereof, wherein;

Z is absent or selected from phenyl substituted with 0-3 R<sup>b</sup> and pyridyl substituted with 0-3 R<sup>b</sup>;

```
15  Ua is absent or is 0;
```

X<sup>a</sup> is absent or is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>;

Y<sup>a</sup> is absent or is 0;

Z<sup>a</sup> is selected from H, phenyl substituted with 0-3 R<sup>c</sup>,  
pyridyl substituted with 0-3 R<sup>c</sup>, and quinolinyl  
substituted with 0-3 R<sup>c</sup>;

25 provided that Z, U<sup>a</sup>, Y<sup>a</sup>, and Z<sup>a</sup> do not combine to form a  
N-N, N-O, O-N, or O-O group;

R<sup>1</sup> is selected from H, CH<sub>3</sub>, and CH<sub>2</sub>CH<sub>3</sub>;

$R^2$  is selected from Q,  $C_{1-6}$  alkylene-Q,  $C_{2-6}$  alkynylene-Q,  $C(O)(CR^aRa^1)_r-Q$ ,  $C(O)O(CR^aRa^1)_r-Q$ ,  $C(O)NR^a(CR^aRa^1)_r-Q$ , and  $S(O)_p(CR^aRa^1)_r-Q$ ;

5 Q is selected from H, cyclopropyl substituted with 0-1  $R^d$ , cyclobutyl substituted with 0-1  $R^d$ , cyclopentyl substituted with 0-1  $R^d$ , cyclohexyl substituted with 0-1  $R^d$ , phenyl substituted with 0-2  $R^d$  and a  
 10 heteroaryl substituted with 0-3  $R^d$ , wherein the heteroaryl is selected from pyridyl, quinolinyl, thiazolyl, furanyl, imidazolyl, and isoxazolyl;

$R^a$ , at each occurrence, is independently selected from H,  $CH_3$ , and  $CH_2CH_3$ ;

15  $R^{a1}$ , at each occurrence, is independently selected from H,  $CH_3$ , and  $CH_2CH_3$ ;

$R^{a2}$ , at each occurrence, is independently selected from H,  
 20  $CH_3$ , and  $CH_2CH_3$ ;

$R^b$ , at each occurrence, is independently selected from  $C_{1-4}$  alkyl,  $OR^a$ , Cl, F, =O,  $NR^aRa^1$ ,  $C(O)R^a$ ,  $C(O)OR^a$ ,  $C(O)NR^aRa^1$ ,  $S(O)_2NR^aRa^1$ ,  $S(O)_pR^{a2}$ , and  $CF_3$ ;

25  $R^c$ , at each occurrence, is independently selected from  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, =O,  $NR^aRa^1$ ,  $C(O)R^a$ ,  $C(O)NR^aRa^1$ ,  $S(O)_2NR^aRa^1$ ,  $S(O)_pR^{a2}$ , and  $CF_3$ ;

30  $R^d$ , at each occurrence, is independently selected from  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, =O,  $NR^aRa^1$ ,  $C(O)R^a$ ,  $C(O)NR^aRa^1$ ,  $S(O)_2NR^aRa^1$ ,  $S(O)_pR^{a2}$ ,  $CF_3$  and phenyl;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, and 3;

5 r<sup>1</sup>, at each occurrence, is selected from 0, 1, 2, and 3;  
and,

s and s<sup>1</sup> combine to total 2, 3, or 4.

10

5. A compound according to Claim 2, wherein;

A is selected from -CO<sub>2</sub>H, CH<sub>2</sub>CO<sub>2</sub>H, -CONHOH, -CONHOR<sup>5</sup>,  
-N(OH)CHO, and -N(OH)COR<sup>5</sup>;

15

ring B is a 4-7 membered non-aromatic carbocyclic or  
heterocyclic ring comprising: carbon atoms, 0-1  
carbonyl groups, 0-1 double bonds, and from 0-2 ring  
heteroatoms selected from O, N, and NR<sup>2</sup>, provided  
20 that ring B contains other than a O-O bond;

Z is absent or selected from a C<sub>5-6</sub> carbocycle substituted  
with 0-3 R<sup>b</sup> and a 5-6 membered heteroaryl comprising  
carbon atoms and from 1-4 heteroatoms selected from  
25 the group consisting of N, O, and S(O)<sub>p</sub> and  
substituted with 0-3 R<sup>b</sup>;

U<sup>a</sup> is absent or is selected from: O, NR<sup>a1</sup>, C(O), C(O)NR<sup>a1</sup>,  
S(O)<sub>p</sub>, and S(O)<sub>p</sub>NR<sup>a1</sup>;

30

X<sup>a</sup> is absent or selected from C<sub>1-2</sub> alkylene, C<sub>2-4</sub>  
alkenylene, and C<sub>2-4</sub> alkynylene

Y<sup>a</sup> is absent or selected from O and NR<sup>a1</sup>;



$Z^a$  is selected from H, a  $C_{5-6}$  carbocycle substituted with  
 0-3  $R^c$  and a 5-10 membered heteroaryl comprising  
 carbon atoms and from 1-4 heteroatoms selected from  
 5 the group consisting of N, O, and  $S(O)_p$  and  
 substituted with 0-3  $R^c$ ;

provided that Z,  $U^a$ ,  $Y^a$ , and  $Z^a$  do not combine to form a  
 N-N, N-O, O-N, O-O,  $S(O)_p$ -O, O- $S(O)_p$  or  $S(O)_p$ - $S(O)_p$   
 10 group;

$R^1$  is selected from H,  $C_{1-4}$  alkyl, phenyl, and benzyl;

$R^2$  is  $(CR^aR^{a1})_rO(CR^aR^{a1})_r-Q$  or  $(CR^aR^{a1})_rNR^a(CR^aR^{a1})_r-Q$ ;  
 15

$Q$  is selected from H, a  $C_{3-6}$  carbocycle substituted with  
 0-3  $R^d$  and a 5-10 membered heterocycle comprising:  
 carbon atoms and 1-4 heteroatoms selected from the  
 group consisting of N, O, and  $S(O)_p$  and substituted  
 20 with 0-3  $R^d$ ;

$R^a$ , at each occurrence, is independently selected from H,  
 $C_{1-4}$  alkyl, phenyl and benzyl;

25  $R^{a1}$ , at each occurrence, is independently selected from H  
 and  $C_{1-4}$  alkyl;

$R^{a2}$ , at each occurrence, is independently selected from  
 $C_{1-4}$  alkyl, phenyl and benzyl;

30  $R^b$ , at each occurrence, is independently selected from  
 $C_{1-4}$  alkyl,  $OR^a$ , Cl, F, =O,  $NR^aR^{a1}$ ,  $C(O)R^a$ ,  $C(O)OR^a$ ,  
 $C(O)NR^aR^{a1}$ ,  $S(O)_2NR^aR^{a1}$ ,  $S(O)_pR^{a2}$ , and  $CF_3$ ;

$R^c$ , at each occurrence, is independently selected from  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, =O,  $NR^aR^{a1}$ ,  $C(O)R^a$ ,  $C(O)NR^aR^{a1}$ ,  $S(O)_2NR^aR^{a1}$ ,  $S(O)_pR^{a2}$ , and  $CF_3$ ;

5

$R^d$ , at each occurrence, is independently selected from  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, =O,  $NR^aR^{a1}$ ,  $C(O)R^a$ ,  $C(O)NR^aR^{a1}$ ,  $S(O)_2NR^aR^{a1}$ ,  $S(O)_pR^{a2}$ ,  $CF_3$  and phenyl;

10  $R^5$ , at each occurrence, is selected from  $C_{1-4}$  alkyl substituted with 0-2  $R^b$ , and  $C_{1-4}$  alkyl substituted with 0-2  $R^e$ ;

$R^e$ , at each occurrence, is selected from phenyl substituted with 0-2  $R^b$  and biphenyl substituted with 0-2  $R^b$ ;

15

$p$ , at each occurrence, is selected from 0, 1, and 2;

20  $r$ , at each occurrence, is selected from 0, 1, 2, 3, and 4; and,

$r^1$ , at each occurrence, is selected from 0, 1, 2, 3, and 4.

25

6. A compound according to Claim 5, wherein;

A is -CONHOH;

30

ring B is a 5-6 membered non-aromatic carbocyclic or heterocyclic ring comprising: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring

heteroatoms selected from O, N, and  $\text{NR}^2$ , provided  
that ring B contains other than a O-O bond;

Z is absent or selected from phenyl substituted with 0-3  
5  $\text{R}^b$  and pyridyl substituted with 0-3  $\text{R}^b$ ;

$\text{U}^a$  is absent or is O;

$\text{X}^a$  is absent or is  $\text{CH}_2$  or  $\text{CH}_2\text{CH}_2$ ;  
10

$\text{Y}^a$  is absent or is O;

$\text{Z}^a$  is selected from H, phenyl substituted with 0-3  $\text{R}^c$ ,  
pyridyl substituted with 0-3  $\text{R}^c$ , and quinolinyl  
15 substituted with 0-3  $\text{R}^c$ ;

provided that Z,  $\text{U}^a$ ,  $\text{Y}^a$ , and  $\text{Z}^a$  do not combine to form a  
N-N, N-O, O-N, or O-O group;

20  $\text{R}^1$  is selected from H,  $\text{CH}_3$ , and  $\text{CH}_2\text{CH}_3$ ;

$\text{R}^2$  is  $(\text{CR}^a\text{R}^a)^1_{\text{r}}\text{O}(\text{CR}^a\text{R}^a)^1_{\text{r}}\text{Q}$  or  $(\text{CR}^a\text{R}^a)^1_{\text{r}}\text{NR}^a(\text{CR}^a\text{R}^a)^1_{\text{r}}\text{Q}$ ;

Q is selected from H, cyclopropyl substituted with 0-1  
25  $\text{R}^d$ , cyclobutyl substituted with 0-1  $\text{R}^d$ , cyclopentyl  
substituted with 0-1  $\text{R}^d$ , cyclohexyl substituted with  
0-1  $\text{R}^d$ , phenyl substituted with 0-2  $\text{R}^d$ , and a  
heteroaryl substituted with 0-3  $\text{R}^d$ , wherein the  
heteroaryl is selected from pyridyl, quinolinyl,  
30 thiazolyl, furanyl, imidazolyl, and isoxazolyl;

$\text{R}^a$ , at each occurrence, is independently selected from H,  
 $\text{CH}_3$ , and  $\text{CH}_2\text{CH}_3$ ;

$R^{a1}$ , at each occurrence, is independently selected from H,  $CH_3$ , and  $CH_2CH_3$ ;

5  $R^{a2}$ , at each occurrence, is independently selected from H,  $CH_3$ , and  $CH_2CH_3$ ;

$R^b$ , at each occurrence, is independently selected from  $C_{1-4}$  alkyl,  $OR^a$ , Cl, F, =O,  $NR^aR^{a1}$ ,  $C(O)R^a$ ,  $C(O)OR^a$ ,  
10  $C(O)NR^aR^{a1}$ ,  $S(O)_2NR^aR^{a1}$ ,  $S(O)_pR^{a2}$ , and  $CF_3$ ;

$R^c$ , at each occurrence, is independently selected from  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, =O,  $NR^aR^{a1}$ ,  $C(O)R^a$ ,  
15  $C(O)NR^aR^{a1}$ ,  $S(O)_2NR^aR^{a1}$ ,  $S(O)_pR^{a2}$ , and  $CF_3$ ;

$R^d$ , at each occurrence, is independently selected from  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, =O,  $NR^aR^{a1}$ ,  $C(O)R^a$ ,  
 $C(O)NR^aR^{a1}$ ,  $S(O)_2NR^aR^{a1}$ ,  $S(O)_pR^{a2}$ ,  $CF_3$  and phenyl;

20  $p$ , at each occurrence, is selected from 0, 1, and 2;

$r$ , at each occurrence, is selected from 0, 1, 2, and 3;  
and,

25  $r^1$ , at each occurrence, is selected from 0, 1, 2, and 3.

7. A compound according to Claim 1, wherein the compound is selected from the group:

30  $N-\{(1R,2S)-2-[(\text{hydroxyamino})\text{carbonyl}]\text{cyclopentyl}\}-2'-(\text{trifluoromethyl})[1,1'\text{-biphenyl}]-4\text{-carboxamide}$

35  $N-\{(1R,2S)-2-[(\text{hydroxyamino})\text{carbonyl}]\text{cyclopentyl}\}-4-[2-(\text{trifluoromethyl})\text{phenoxy}]\text{benzamide}$

- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(3-methyl-2-pyridinyl)benzamide
- 5 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}[1,1'-biphenyl]-4-carboxamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-phenoxybenzamide
- 10 4-(benzyloxy)-*N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide
- 15 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-methoxy[1,1'-biphenyl]-4-carboxamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-methyl[1,1'-biphenyl]-4-carboxamide
- 20 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(2-methoxyphenoxy)benzamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(2-methylphenoxy)benzamide
- 25 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(3-methylphenoxy)benzamide
- 30 4-(5,8-dihydro-4-quinolinyl)-*N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-3',5'-dimethyl[1,1'-biphenyl]-4-carboxamide
- 35 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-6-(2-methylphenyl)nicotinamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-6-(2-methoxyphenyl)nicotinamide
- 40 (3*S*,4*S*)-*N*-hydroxy-1-isopropyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 45 (3*S*,4*S*)-1-(2,2-dimethylpropanoyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 50 (3*S*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(methylsulfonyl)-3-pyrrolidinecarboxamide

- (3*S*, 4*S*)-*N*-hydroxy-1-methyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 5    *tert*-butyl (3*S*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 10    (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 15    *tert*-butyl 4-[cis-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)pyrrolidinyl]-1-piperidinecarboxylate
- 20    *cis*-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(4-piperidinyl)-3-pyrrolidinecarboxamide
- 25    *cis*-1-[3-[(1,1-dimethylethoxy)carbonyl]pyrrolidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 30    *cis*-*N*-hydroxy-1-[3-pyrrolidinyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 35    *tert*-butyl (3*R*, 4*R*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 40    *tert*-butyl (3*S*, 4*R*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 45    (3*S*, 4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 50    *tert*-butyl (3*R*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 50    (3*R*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 50    *N*-{(1*R*, 2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(4-pyridinyl)benzamide

- (3*S*, 4*S*)-1-(1,1-dimethyl-2-propynyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide  
 5
- (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-propynyl)-3-pyrrolidinecarboxamide
- 10 (3*S*, 4*S*)-1-allyl-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-propyl-3-pyrrolidinecarboxamide
- 20 (3*S*, 4*S*)-*N*-hydroxy-1-(2-methyl-2-propenyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 25 (3*S*, 4*S*)-1-(1,1-dimethyl-2-propenyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-*tert*-pentyl-3-pyrrolidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-1-isopentyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 35 (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-neopentyl-3-pyrrolidinecarboxamide
- 40 (3*S*, 4*S*)-1-butyl-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 45 (3*S*, 4*S*)-1-(3-butenyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3*S*, 4*S*)-1-(2-butyryl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

- (3*S*, 4*S*)-1-(2-furylmethyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 5 (3*S*, 4*S*)-*N*-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 10 (3*R*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-3-furancarboxamide
- 15 (3*S*, 4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-3-furancarboxamide
- 20 (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(1,3-thiazol-2-ylmethyl)-3-pyrrolidinecarboxamide
- (3*S*, 4*S*)-1-acetyl-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 25 (3*S*, 4*S*)-*N*-hydroxy-1-isobutyryl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-1-(3-methylbutanoyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 35 (3*S*, 4*S*)-1-(cyclopropylcarbonyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 40 (3*S*, 4*S*)-1-(cyclobutylcarbonyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-1-(methoxyacetyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 45 (3*S*, 4*S*)-1-(2-furoyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 50 (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-thienylcarbonyl)-3-pyrrolidinecarboxamide



- (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-propionyl-3-pyrrolidinecarboxamide  
 5
- (3*R*, 4*S*)-4-{[4-(2-butynyloxy)benzoyl]amino}-*N*-hydroxy-tetrahydro-3-furancarboxamide
- 10 *N*-{(1*R*, 2*S*)-2-[(hydroxyamino)carbonyl]-4-oxocyclopentyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 15 *N*-{(1*R*, 2*S*, 4*R*)-4-hydroxy-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 20 *N*-{(1*R*, 2*S*, 4*S*)-4-hydroxy-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-tetrahydro-2*H*-pyran-4-yl-3-pyrrolidinecarboxamide
- 25 methyl (3*S*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 30 ethyl (3*S*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 35 propyl (3*S*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 40 allyl (3*S*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 45 isopropyl (3*S*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 50 2-propynyl (3*S*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 2-butynyl (3*S*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate

- 3-butenyl (3*S*,4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 5 benzyl (3*S*,4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 10 *N*-{(1*R*,2*S*)-4-(dimethylamino)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- (3*S*,4*S*)-4-{[4-(2-butynyloxy)benzoyl]amino}-*N*-hydroxy-1-isopropyl-3-pyrrolidinecarboxamide
- 15 *N*-{(1*R*,2*S*)-4,4-difluoro-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 20 (3*S*,4*S*)-*N*-hydroxy-1-isopropyl-4-{[4-(2-methylphenoxy)benzoyl]amino}-3-pyrrolidinecarboxamide
- 25 *cis-N*-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide
- trans-N*-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide
- 30
- (1*S*,2*R*)-*N*-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide
- 35
- (1*R*,2*S*)-*N*-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide
- 40 *cis-N*-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclohexanecarboxamide
- trans-N*-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclohexanecarboxamide
- 45
- trans*-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 50

- trans-N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 5 *cis*-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 10 *cis-N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 15 (3*S*,4*R*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 20 (3*S*,4*S*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 25 (3*S*,4*S*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 30 (3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 35 (3*S*,4*R*)-1-[(butoxy)carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 40 (3*S*,4*R*)-*N*-hydroxy-1-[[[(1-methylethyl)oxy]carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 45 (3*S*,4*R*)-*N*-hydroxy-1-(methylsulfonyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(phenylsulfonyl)-3-piperidinecarboxamide

- (3*S*,4*R*)-1-acetyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 5 (3*S*,4*R*)-1-benzoyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 10 (3*S*,4*R*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 15 (3*S*,4*R*)-1-(3,3-dimethylbutanoyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 20 (3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-3-piperidinecarboxamide
- (3*S*,4*R*)-1-(dimethylcarbonyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 25 (3*S*,4*R*)-*N*-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 30 (3*S*,4*R*)-1-ethyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 35 (3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-propyl-3-piperidinecarboxamide
- 40 (3*S*,4*R*)-*N*-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3*S*,4*R*)-1-(cyclopropylmethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 45 (3*S*,4*R*)-1-(2,2-dimethylpropyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 50 (3*S*,4*R*)-1-benzyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

- 5 (3*S*, 4*R*)-1-(2-thiazolylmethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 10 (3*S*, 4*S*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*R*, 4*S*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 20 (3*R*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-*N*-hydroxy-1-[[[(2-methylpropyl)oxy]carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-1-(methoxycarbonyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 35 (3*S*, 4*S*)-*N*-hydroxy-1-[(1-methylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 40 (3*S*, 4*S*)-*N*-hydroxy-1-(methylsulfonyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 45 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(phenylsulfonyl)-4-piperidinecarboxamide
- (3*S*, 4*S*)-1-(3,3-dimethylbutanoyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

- (3*S*, 4*S*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-1-benzoyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-1-[(pyridin-3-yl)carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-thiophenecarbonyl)-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-1-(dimethylcarbamyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[[2-(2-thienyl)ethyl]carbamyl]-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-1-[(1,1-dimethylethyl)carbamyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 35 (3*S*, 4*S*)-*N*-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 40 (3*S*, 4*S*)-1-ethyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 45 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-propyl-4-piperidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

- (3*S*,4*S*)-1-cyclobutyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*S*,4*S*)-1-butyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-methylpropyl)-4-piperidinecarboxamide
- 15 (3*S*,4*S*)-1-(cyclopropylmethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 20 (3*S*,4*S*)-1-(2,2-dimethylpropyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*,4*S*)-1-cyclopentyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropyranyl)-4-piperidinecarboxamide
- 30 (3*S*,4*S*)-1-benzyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 35 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-thiazolylmethyl)-4-piperidinecarboxamide
- 40 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-pyridinylmethyl)-4-piperidinecarboxamide
- (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-pyridinylmethyl)-4-piperidinecarboxamide
- 45 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-pyridinylmethyl)-4-piperidinecarboxamide
- 50 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(*trans*-3-phenyl-2-propenyl)-4-piperidinecarboxamide

- 5 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-phenyl-4-piperidinecarboxamide
- (3*R*, 4*S*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*R*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-methyl-4-piperidinecarboxamide
- 15 (3*R*, 4*S*)-1-(dimethylcarbamyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-1-hexyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-1-(2-fluoroethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*, 4*S*)-1-(2,2-difluoroethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-1-(1-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 35 (3*S*, 4*S*)-1-(1-ethylpropyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 40 (3*S*, 4*S*)-1-[1-[(1,1-dimethylethyl)oxy]carbonyl]-4-tetrahydropiperidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 45 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropiperidinyl)-4-piperidinecarboxamide
- 50 (3*S*, 4*S*)-1-[1-[(1,1-dimethylethyl)oxy]carbonyl]-3-tetrahydropyrrolidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide



- (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-tetrahydropyrrolidinyl)-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-1-(1,1-dimethyl-2-propynyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-thiophenylmethyl)-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-1-[2-(*N,N*-dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 35 (3*S*, 4*S*)-1-(*t*-butylsulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 40 (3*S*, 4*S*)-1-(*t*-butylsulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 45 (3*S*, 4*S*)-1-(benzenesulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*, 4*S*)-1-(*t*-butylsulfinyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

- (3*S*, 4*S*)-*N*-hydroxy-1-(2-hydroxyethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-1-[2-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]ethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-1-(2-aminoethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-1-[2-(*N,N*-dimethylamino)ethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-1-[(2*S*)-2-aminopropyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-1-[(2*R*)-2-amino-3-hydroxypropyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[(2*R*)-2-pyrrolidinyl]methyl]-4-piperidinecarboxamide
- 35 (3*S*, 4*R*)-*N*-hydroxy-1-(2-hydroxyethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 40 (3*S*, 4*R*)-1-(2-aminoethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 45 (3*R*, 4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-2*H*-pyran-3-carboxamide
- 50 (3*S*, 4*S*)-1-tert-butyl-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide

- 5 *tert*-butyl 2-[(3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate
- 10 2-[(3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoic acid
- 15 methyl 2-[(3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate
- (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide
- 20 (3*S*,4*S*)-1-[2-(dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 25 (3*S*,4*S*)-1-(1,1-dimethyl-2-propenyl)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 30 (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-*tert*-pentyl-4-piperidinecarboxamide
- 35 (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-propynyl)-4-piperidinecarboxamide
- 40 (3*S*,4*S*)-1-allyl-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 45 (3*S*,4*S*)-*N*-hydroxy-1-(1-methyl-2-propynyl)-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide

- N*-{(1*R*,2*S*)-4,5-dihydroxy-2-  
[(hydroxyamino)carbonyl]cyclohexyl}-4-[(2-methyl-4-  
quinolinyl)methoxy]benzamide
- 5 (5*S*)-*N*-hydroxy-5-({4-[(2-methyl-4-  
quinolinyl)methoxy]benzoyl}amino)-2-oxo-4-  
piperidinecarboxamide
- 10 (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-  
quinolinyl)methoxy]benzoyl}amino)-2-oxo-4-  
piperidinecarboxamide
- 15 (3*S*,4*S*)-3-{[4-(2-butynyloxy)benzoyl]amino}-*N*-hydroxy-1-  
isopropyl-4-piperidinecarboxamide
- (3*S*,4*S*)-3-{[4-(2-butynyloxy)benzoyl]amino}-*N*-hydroxy-4-  
piperidinecarboxamide
- 20 *tert*-butyl (3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-  
methyl-3-pyridinyl)methoxy]benzoyl}amino)-1-  
piperidinecarboxylate
- 25 (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-3-  
pyridinyl)methoxy]benzoyl}amino)-4-  
piperidinecarboxamide
- tert*-butyl (3*S*,4*S*)-3-({4-[(2,5-  
dimethylbenzyl)oxy]benzoyl}amino)-4-  
30 [(hydroxyamino)carbonyl]-1-piperidinecarboxylate
- (3*S*,4*S*)-3-({4-[(2,5-dimethylbenzyl)oxy]benzoyl}amino)-*N*-  
hydroxy-4-piperidinecarboxamide
- 35 (cis,cis)-3-Amino-2-[[[4-[(2-methyl-4-  
quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-  
hydroxy)cyclohexylcarboxamide
- 40 (cis,cis)-3-Methylamino-2-[[[4-[(2-methyl-4-  
quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-  
hydroxy)cyclohexylcarboxamide
- 45 (cis,cis)-3-Dimethylmino-2-[[[4-[(2-methyl-4-  
quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(*N*-  
hydroxy)cyclohexylcarboxamide

- (*cis,trans*)-3-Amino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(N-hydroxy)cyclohexylcarboxamide
- 5 (*cis,trans*)-3-Dimethylmino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide
- 10 (*cis,trans*)-3-(1-Methyl-1-ethylmino)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide
- 15 (*cis,trans*)-3-Methylamino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide
- 20 (*cis,cis*)-3-Hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-{[(2-methyl-4-quinolinyl)methyl]amino}benzamide
- 25 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-{methyl[(2-methyl-4-quinolinyl)methyl]amino}benzamide
- 30 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-(3-phenyl-4,5-dihydro-5-isoxazolyl)benzamide
- 35 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(3-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(2-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 40 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-quinolinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 45 4-[3-(2,6-Dimethyl-4-pyridinyl)-4,5-dihydro-5-isoxazolyl]-*N*-{*cis*-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-3-methoxy-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 50

- 3-Hydroxy-*N*-{*cis*-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 5 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[5-(2-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[5-(4-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide
- 10 *N*-{4-[(hydroxyamino)carbonyl]-3-pyrrolidinyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-5-carboxamide
- 15 *N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-5-carboxamide
- N*-hydroxy-3-({6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthoyl}amino)-4-piperidinecarboxamide
- 20 *N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthamide
- N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-2-naphthamide
- 25 *N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-1,2,3,4-tetrahydro-1-isoquinolinecarboxamide
- 30 *N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-benzimidazole-5-carboxamide
- N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-4-carboxamide
- 35 (±)-*cis-N*-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-cycloheptanecarboxamide
- 40 (±)-*trans-N*-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-cycloheptanecarboxamide
- (4*S*,5*R*)-*N*-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxohexahydro-1*H*-azepine-4-carboxamide
- 45 (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-4-carboxamide
- 50

- (3*S*, 4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-3-carboxamide
- 5 (4*S*, 5*R*)-*N*-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-4-carboxamide
- 10 (2*S*, 3*R*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-pyrrolidinecarboxamide
- 15 (2*R*, 3*R*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-pyrrolidinecarboxamide, and
- tert-butyl (2*S*, 3*R*)-2-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 20 or a pharmaceutically acceptable salt form thereof.

8. A pharmaceutical composition, comprising: a  
 25 pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt form thereof.

30 9. A method of treating a condition or disease mediated by MMPs, TNF, aggrecanase, or a combination thereof in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 1 or a  
 35 pharmaceutically acceptable salt form thereof.

10. A method of treating according to Claim 9, wherein the disease or condition is referred to as acute  
 40 infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune

disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease, cardiovascular effects, chronic fatigue syndrome, chronic obstruction pulmonary disease, 5 coagulation, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, HIV 10 infection, hyperoxic alveolar injury, infectious arthritis, inflammation, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, 15 periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pyoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, 20 sepsis syndrome, Still's disease, shock, Sjogren's syndrome, skin inflammatory diseases, solid tumor growth and tumor invasion by secondary metastases, spondylitis, stroke, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis.